Search

Methicillin-Resistant Staphylococcus aureus (MRSA) infections became difficult to cure as they expanded over the world. Because Staphylococcus aureus can cause a variety of illnesses in the body, MRSA infections, in particular, can be acquired in healthcare settings (HA-MRSA) and community settings (CA-MRSA). MRSA infections have been demonstrated to be resistant to penicillin, -lactam, and vancomycin, as well as other antimicrobials, restricting their treatment choices. Their susceptibility testing was examined using morphological, molecular, and new methodologies. Because it was resistant to numerous antibiotics, it was important to develop new agents for therapy; this article covers the current use of antibiotics, which include linezolid and daptomycin. This article discusses the mechanism of action, antibacterial activity, clinical perspectives, resistance, and side effects of the antibiotics: linezolid and daptomycin. Different antibiotics were tested in various parts of the world, and the results revealed that practically all antibiotics are resistant to MRSA infections, with linezolid and daptomycin in particular showing resistance at a very low ratio. As a result, linezolid and daptomycin are preferred for treatment; the following article also discusses their benefits and drawbacks for humans. Similarly, it focused on the developing threats to linezolid and daptomycin antibiotics. Combination therapy should be considered for the decrease of resistance to these antibiotics. The present paper seeks to provide a current and up-to-date review of antibiotic susceptibility testing for MRSA.